WeVote
Log In

Bill

Bill

SB 78

Public Health – Prostate–Specific Antigen Testing (Protect Our Prostate Act)

2026 Regular Session Introduced by Arthur Ellis

Maryland bill establishing PSA testing requirements, likely involving informed consent or coverage mandates, amid medical debate over screening effectiveness and necessity.

Hearing 2/12 at 1:00 p.m.
0
WeVote Research Nonpartisan
Bill Summary · SB 78

Legislative bill overview

SB 78, the "Protect Our Prostate Act," would establish requirements around prostate-specific antigen (PSA) testing in Maryland. Based on the bill title and common legislative patterns, it likely mandates informed consent procedures, insurance coverage, or specific counseling requirements before PSA screening. The exact provisions require review of the bill text, as the summary materials provided do not detail specific requirements.

Why is this important

PSA testing is medically controversial—major health organizations including the U.S. Preventive Services Task Force recommend against routine screening due to high false-positive rates and unnecessary biopsies, yet many men and physicians favor the option. Legislation in this area directly affects healthcare access, insurance costs, and patient autonomy in screening decisions. Maryland's approach could influence prostate cancer detection practices and health outcomes across the state.

Potential points of contention

  • Medical evidence disagreement: Conflict between organizations recommending against routine PSA screening and those supporting patient choice and early detection
  • Insurance and cost implications: Mandating coverage or counseling requirements may increase healthcare costs or insurance premiums
  • Patient autonomy versus paternalism: Balancing informed consent/counseling requirements with concerns about restricting access or imposing administrative burden on providers

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.